[Myasthenia and muscle relaxants]

Area of Science:

• Anesthesiology
• Neurology
• Pharmacology

Background:

• Myasthenia gravis is a neuromuscular disease affecting voluntary muscle function.
• General anesthesia and surgical procedures pose unique challenges in myasthenia gravis patients.
• Understanding the impact of neuromuscular blocking agents is crucial for safe anesthetic management.

Purpose of the Study:

• To evaluate the duration of action of atracurium and vecuronium in myasthenia gravis patients during surgery.
• To identify factors influencing the response to neuromuscular blocking agents in this patient population.

Main Methods:

• Retrospective analysis of 18 myasthenia gravis patients undergoing surgery under general anesthesia.
• Administration of atracurium (0.3 mg/kg) and vecuronium (0.06 mg/kg) for neuromuscular blockade.
• Observation and recording of the duration of action of the neuromuscular blocking agents.

Main Results:

• Atracurium and vecuronium demonstrated a prolonged duration of action in myasthenia gravis patients.
• The most significant prolongation of effect was observed in patients with severe myasthenia gravis.
• 14 patients underwent thymectomy, while 2 had emergency procedures (cesarean section, laparotomy).

Conclusions:

• The severity of myasthenia gravis influences the duration of action of atracurium and vecuronium.
• Anesthetic management for myasthenia gravis patients requires careful consideration of neuromuscular blocking agent pharmacodynamics.
• Further research is warranted to optimize anesthetic protocols for myasthenia gravis surgery.